CRISPR Therapeutics for Pancreatic Cancer

Pancreatic cancer is one of the most fatal cancers with a five-year survival rate of just 7.2%. The current treatments available for pancreatic cancer are often unsuccessful, creating a pressing need for more effective therapeutic options. CRISPR gene editing has emerged as a powerful tool with the potential to revolutionize cancer treatment strategies. Experiments using CRISPR in animal models have proven successful in stopping pancreatic cancer progression. This versatile technology can be used to edit, silence, or disrupt genes, presenting a novel avenue for treating genetic cases of pancreatic cancer in patients. In this review, I discuss the history behind CRISPR and its promising role in reshaping therapeutic approaches for pancreatic cancer.